GENFIT CORP.
245 First Street - 18th Floor
Suite 1806
Cambridge
Massachusetts
02142
United States
Tel: 617-444-8416
Fax: 617- 444-8405
Website: http://www.genfit.com/
Email: Karen.Miller@Genfit.com
About GENFIT CORP.
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
232 articles about GENFIT CORP.
-
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH
11/18/2021
GENFIT is proud to announce that NIS4® technology’s utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis.
-
GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program
11/9/2021
Lille, France; Cambridge, MA; November 09, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced the first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program.
-
GENFIT: Third Quarter 2021 Financial Information
11/8/2021
Lille, France; Cambridge, MA; November 8, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced its cash position as of September 30, 2021 and revenues for the first nine months of 20211.
-
Instead of continuing to develop the two different assets, EDP-305 and EDP-297, the company intends to seek an out-licensing deal to focus on infectious respiratory diseases.
-
GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update
9/29/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced its first half-year financial results and provided a corporate update.
-
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
7/9/2021
Lille, France; Cambridge, MA; July09, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
-
GENFIT: June 30, 2021 Annual Shareholders Meeting results
6/30/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, announced the results of the voting by shareholders at the Combined Shareholders Meeting which took place on June 30, 2021 behind closed doors at the Company’s headquarters.
-
GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan
6/24/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the securing of a €11 million non-dilutive loan guaranteed by the French government.
-
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening
6/15/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced that the June 15, 2021 Combined Shareholders Meeting obtained a wide support for the resolutions submitted to the shareholders vote, however, quorum was not met on first convening.
-
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
5/27/2021
GENFIT informs its shareholders of certain participation and organization procedures for the ordinary and extraordinary general meeting of June 15, 2021 in accordance with decree n°2021-255 of March 9, 2021, extending the application of measures of ordinance n°2020-321 of March 25, 2020 and its application decree n°2020-418 of April 10, 2020 which was extended until July 31, 2021 by the decree n°2021-255 of March 9, 2021.
-
GENFIT: Reports First Quarter 2021 Financial Information
5/12/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced its cash position as of March 31, 2021 and revenues for the first three months of 2021.
-
GENFIT Provides Pipeline Update and Launch of New Clinical Programs
5/11/2021
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced a refocus of its R&D on acute on chronic liver failure and cholestatic diseases.
-
GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents
5/10/2021
GENFIT announced that it published in the May 10, 2021 French legal announcements bulletin n°56 its convening notice that the Combined Shareholders Meeting will be held on June 15, 2021, at 2:30pm, at the Company’s headquarters, located at Parc Eurasanté, 885 avenue Eugène Avinée in Loos, France.
-
GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH
5/3/2021
Lille, France; Cambridge, MA;May 3, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the launch of NASHnext®, a novel, noninvasive diagnostic test for nonalcoholic steatohepatitis.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
BioSpace Movers & Shakers, Jan. 29
1/29/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
BioSpace Global Roundup, Oct. 1
10/1/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices. -
BioSpace Global Roundup, Aug. 6
8/6/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Clinical Catch-Up: July 20-24
7/27/2020
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.